GSK plc

NYSE:GSK

Drug Manufacturers - General

Healthcare
$48.58 -2.56%

-$1.34 today

Market cap
$97.53B
Beta
0.29
P/E (TTM)
13.3
EPS (TTM)
$1.45
Dividend yield
3.48%
52W Low $35.45High $61.70

Volume 2.02M

Average 4.07M

GSK Operating Income

Profit from core operations after operating expenses, before interest and taxes.

GSK plcNYSE: GSK

Operating Income · Q2 FY2026 · quarter ended Jun 2026

Operating income dips below year-ago levels

Q2 FY2026 operating income of £481M fell 76.2% year over year, behind the +34.1% change in trailing-twelve-month operating income. Sequentially, it fell 79.0% from the prior quarter. Over 3 fiscal years it compounded at +9.0% a year.

Context

  • Operating income amounted to 25.5% of revenue in FY2025, up 12.7 pp from a year earlier.
  • Operating income increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether operating income reaches the consensus estimate from 16 analysts of £9.37B (+12.4%) for the fiscal year ending Dec 2026, a slowdown from the +107.4% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
£481M-79.0% QoQ
Last fiscal yearDec 2025
£8.34B+107.4% YoY
LTMJun 2026
£6.87B+34.1% YoY
Operating Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-76.2%+0.0%+76.3 pp
1 year+107.4%+12.4%-95.0 pp
3-year CAGR+9.0%+7.4%-1.7 pp
5-year CAGR+5.8%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Operating Income history

GBP · from the income statement

Latest · FY2025
8.34B GBP
Year-over-year change
+107.4%
4-year CAGR
+17.6%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Operating Income vs competitors

How GSK compares with its peers on the latest reported figures

  • Peers report in different currencies, so operating income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +34.1% is the 3rd highest of 10, against a peer median of +2.2%.
  • Operating income amounts to 20.7% of revenue for GSK, versus a peer median of 26.7%.
GSK Competitors
Operating Income for GSK and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NVONovo Nordisk A/SLTM Jun 2026DKK 142.1B DKK-0.5%+19.5%43.1%
LLYEli Lilly and CompanyLTM Jun 2026$39.61B USD+76.5%+50.8%49.7%
JNJJohnson & JohnsonLTM Sep 2026$25.53B USD+6.2%+6.8%25.7%
PFEPfizer Inc.LTM Jun 2026$17.02B USD+2.2%-23.0%26.7%
NVSNovartis AGLTM Jun 2026$16.99B USD+1.8%+29.0%30.5%
AZNAstraZeneca PLCLTM Sep 2026$14.71B USD+14.9%+54.1%23.7%
AMGNAmgen Inc.LTM Jun 2026$12.65B USD+54.6%+3.7%33.2%
MRKMerck & Co., Inc.LTM Jun 2026$11.06B USD-48.3%+8.7%16.7%
SNYSanofiLTM Jun 2026€7.24B EUR-8.6%-1.9%14.8%
GSKGSK plcLTM Jun 2026£6.87B GBP+34.1%+9.0%20.7%
Peer median (excluding GSK) —+2.2%+8.7%26.7%

Competitors are the stored peer set for GSK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

GBP
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue24.7B29.32B30.33B31.38B32.67B
Cost of Revenue8.16B9.55B8.57B9.05B9.02B
Gross Profit16.53B19.77B21.76B22.33B23.65B
Gross Margin66.9%67.4%71.8%71.2%72.4%
Research & Development5.02B5.49B6.22B6.4B7.53B
Selling, General & Admin7.07B8.37B9.39B11.02B9.09B
Operating Expenses12.18B13.34B15.02B18.31B15.31B
Depreciation & Amortization2.12B2.15B2.29B2.55B2.31B
EBITDA6.49B8.6B9.08B6.67B10.4B
EBITDA Margin26.3%29.3%29.9%21.3%31.8%
Operating Income4.36B6.43B6.75B4.02B8.34B
Operating Margin17.6%21.9%22.2%12.8%25.5%
Interest Income28M64.27M40M67.39M56M
Interest Expense784M855.53M775M657.58M687M
Other Income / Expenses(758M)(805M)(681M)(544M)(937M)
Income Before Tax3.6B5.63B6.06B3.48B7.4B
Pre-Tax Margin14.6%19.2%20.0%11.1%22.7%
Income Tax Expense83M707M756M526M1.11B
Net Income4.39B14.96B4.93B2.58B5.72B
Net Margin17.8%51.0%16.2%8.2%17.5%
EPS (Basic)2.747.442.441.262.82
EPS (Diluted)2.707.322.401.242.78
Weighted Avg Shares1.6B2.01B2.03B2.04B2.03B
Weighted Avg Shares (Diluted)1.62B2.04B2.06B2.07B2.06B

GSK plc

NYSE:GSK

Intrinsic Alpha fair value

Locked

Current Price

$48.58

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.